Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma

Xu, Jiuhui; Chen, Chenglong; Sun, Kunkun; Shi, Qianyu; Wang, Boyang; Huang, Yi; Ren, Tingting; Tang, Xiaodong

doi:10.3389/fonc.2023.1192472

Cited by 2 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to rheumatoid arthritis therapy, the drug is also used to block cytokine release syndrome, a side effect of CAR-T anticancer therapy (Roche Pharma, A. RoActemra, 2013). Furthermore, in a study, Xu et al (2023) showed that tocilizumab either alone or in combined with anlotinib in four osteosarcoma (OS) anlotinib-resistant cell lines, was able to block the tumor progression by inhibiting STAT3 expressions. The IL-6 expression level was high in patients with OS and it is assocciated cowith poor prognosis, but in this case, tocilizumab could reverse anlotinib resistance in OS by IL-6/STAT3 pathway.…”

Section: Ivermectinmentioning

confidence: 99%

Possible Interaction Between Drugs for COVID19 And Cancer Therapy

Marfe,

Kumar Shukla,

Tarro

et al. 2024

clin. med. & helt. res. jour.

View full text Add to dashboard Cite

At the end of 2019, a new disease was reported in Wuhan China and described such as severe acute respiratory syndrome (SARS). This new virus named SARSCoV-2 S is characterized by high infectivity among humans. Such disease can have no symptoms in some individuals, while in others can provoke flu like symptoms or acute respiratory distress syndrome, pneumonia, and death. At the end of January 2020, the World Health Organization and Public Health Emergency of International Concern declared a pandemic status. Many studies showed a high mortality rate in cancer patient infected by SARS-CoV-2 infection. In this context, the decision of a safe and effective treatment against COVID19 plays a crucial role crucial in these patients Therefore, important questions arose: Can the COVID19 therapies protect everyone and above all cancer patients? and which drug interactions can occur between cancer therapy and COVID19 treatment? In this regard, Covid-19 is a new disease and for this reason it will be necessary to modify constantly pharmacological treatment. In this scenario, the potential drug–drug interactions (DDI) in the cancer patients should be considered to evaluate the risks and benefits of drug combinations.

show abstract

Section: Ivermectinmentioning

confidence: 99%

Possible Interaction Between Drugs for COVID19 And Cancer Therapy

Marfe,

Kumar Shukla,

Tarro

et al. 2024

clin. med. & helt. res. jour.

View full text Add to dashboard Cite

show abstract

Enzymatic TET-1 inhibition highlights different epigenetic behaviours of IL-1β and TNFα in tumour progression of OS cell lines

Bellavia,

Caruccio,

Caradonna

et al. 2024

Clin Epigenet

View full text Add to dashboard Cite

Osteosarcoma (OS) is the most frequent primary malignant bone tumour, whose heterogeneity represents a major challenge for common antitumour therapies. Inflammatory cytokines are known to be necessary for OS progression. Therefore, to optimise therapy, it is important to discover reliable biomarkers by identifying the mechanism generating OS and investigating the inflammatory pathways that support the undifferentiated state. In this work, we highlight the differences of epigenetic activities of IL-1β and TNFα, and the susceptibility of TET-1 enzymatic inhibition, in tumour progression of three different OS cell lines. Investigating DNA methylation of IL-6 promoter and determining its expression, we found that TET enzymatic inhibition influences proliferation induced by inflammatory cytokines in OS cell lines. Moreover, Bobcat 339 treatment blocks IL-1β epigenetic action on IL-6 promoter, while only partially those of TNFα as well as inhibits IL-1β-dependent epithelial–mesenchymal transition (EMT) process, but only partially those of TNFα. In conclusion, this work highlights that IL-1β and TNFα have different effects on DNA demethylation in OS cell lines, making DNA methylation a potential biomarker of disease. Specifically, in IL-1β treatment, TET-1 inhibition completely blocks tumour progression, while in TNFα actions, it is only partially effective. Given that these two inflammatory pathways can be therapeutic targets for treating these tumours, knowledge of their distinct epigenetic behaviours can be useful for developing precise and specific therapeutic strategies for this disease. Supplementary Information The online version contains supplementary material available at 10.1186/s13148-024-01745-4.

show abstract

Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma

Cited by 2 publications

References 45 publications

Possible Interaction Between Drugs for COVID19 And Cancer Therapy

Possible Interaction Between Drugs for COVID19 And Cancer Therapy

Enzymatic TET-1 inhibition highlights different epigenetic behaviours of IL-1β and TNFα in tumour progression of OS cell lines

Contact Info

Product

Resources

About